Search
Tizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalInitially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons … Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.
Zopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigational[L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP. … Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081]
Synonyms: DNA (recombinant replication-deficient Gorilla gorilla gorilla adenovirus strain GC4 vector PRGN-2012 human cytomegalovirus promoter plus human papillomavirus 6/11 E2, E4, E6, E7 protein 11 epitope-containing, Replication-deficient gorilla adenovirus vector (strain GC46) encoding human papillomavirus (HPV) type 6 and type 11 antigens comprising 11 epitopes derived from regions of the E2, E4, E6, and E7 proteinsImlifidase
go.drugbank.com/drugs/DB15258ApprovedInvestigational[A225836] As a result, highly sensitized individuals experience marked delays on transplant lists due to the challenges associated with procuring an HLA compatible donor graft. … [A225916] Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.
Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigational[L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer. … Rusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera.
Dexmethylphenidate
go.drugbank.com/drugs/DB06701ApprovedInvestigationalDexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193].
Raxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigational[A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272] … It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnProsomastatin is further process into two active forms, somatostatin-14 (SST-14) and somatostatin-28 (SST-28), an extended SST-14 sequence to the N-terminus [A20384]. … Somatostatin has been used in the clinical setting for the diagnosis of acromegaly and gastrointestinal tract tumours.
Products: DELT-SOMAT®Certolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigationaldone directly in bacterial hosts such as _E. coli_. … [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819]
Products: CIMZIA 200MG PEN, CIMZIA 200 MG ILO IN FEROmadacycline
go.drugbank.com/drugs/DB12455ApprovedInvestigationalOmadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. … Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent
Chlorambucil
go.drugbank.com/drugs/DB00291ApprovedInvestigationalAlthough it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Synonyms: N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid, N,N-di-2-chloroethyl-gamma-p-aminophenylbutyric acid